Loading company…
Cambridge, US oncology biotech with a computational allosteric drug-discovery platform, listed on Nasdaq as RLAY.
Based in Massachusetts, US, and founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko and Matthew Jacobson, Relay Therapeutics, Inc. develops oncology therapeutics through an allosteric drug-discovery platform called Dynamo. The company raised USD 400 million in Series C funding in 2018 led by SB Investment Advisers, and in July 2020 it raised USD 400 million in an IPO, selling 20 million shares at USD 20 on Nasdaq under the ticker RLAY.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in